收藏切换
Meta-analysis of ustekinumab compared with other drugs in second-line treatment for Crohn's disease
收藏切换
Chengzheng LIU1, Xingchen WEI1, Gang FANG1, Yu HU1, Jinxi DING1, 2, *
World Clinical Drug | 2025, 46(6) : 612 - 620
Less
收藏切换
World Clinical Drug | 2025, 46(6): 612-620
• Article •
Meta-analysis of ustekinumab compared with other drugs in second-line treatment for Crohn's disease
Full
Chengzheng LIU1, Xingchen WEI1, Gang FANG1, Yu HU1, Jinxi DING1, 2, *
Affiliations
  • 1.School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
  • 2.Pharmaceutical Market Access Policy Research Center, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
Published: 2025-06-10 doi: 10.13683/j.wph.2025.06.013
Outline
收藏切换
Objective

To systematically evaluate the efficacy and safety of ustekinumab compared with other second-line drugs for Crohn's disease(CD).

Methods

A systematic search of PubMed, Embase, Cochrane Library, and other databases for cohort studies comparing ustekinumab with other second-line therapies for the treatment of CD. Meta-analysis was performed by Review Manager 5.4 software.

Results

A total of 10 literature studies were included, 1 222 patients in ustekinumab group and 949 patients in other drug groups. The results showed that the clinical remission rate[OR=1.75, 95%CI: (1.38, 2.21), P<0.001], steroid-free clinical remission rate[OR=1.54, 95%CI: (1.17, 2.01),P=0.002] and clinical response rate[OR=2.69, 95%CI: (1.10, 6.58), P=0.030] in ustekinumab group were higher than those of the other drug groups. In addition, the incidence of adverse events[OR=0.29, 95%CI: (0.09, 0.96), P=0.040]and discontinuation rate[OR=0.28, 95%CI: (0.17, 0.46), P<0.001] in ustekinumab group were lower than those of the other drug groups.

Conclusion

Ustekinumab is more effective and safer than the other second-line drugs for CD.

ustekinumab  /  second-line threatment  /  Crohn's disease  /  meta-analysis
刘成正, 卫星辰, 方刚, 胡宇, 丁锦希. 乌司奴单抗对比其他药物二线治疗克罗恩病的meta分析. 世界临床药物, 2025 , 46 (6) : 612 -620 . DOI: 10.13683/j.wph.2025.06.013
Chengzheng LIU, Xingchen WEI, Gang FANG, Yu HU, Jinxi DING. Meta-analysis of ustekinumab compared with other drugs in second-line treatment for Crohn's disease[J]. World Clinical Drug, 2025 , 46 (6) : 612 -620 . DOI: 10.13683/j.wph.2025.06.013
Year 2025 volume 46 Issue 6
49
11
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2025.06.013
  • Receive Date:2024-07-17
  • Online Date:2026-11-09
  • Published:2025-06-10
Article Data
Affiliations
History
  • Received:2024-07-17
Affiliations
    1.School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
    2.Pharmaceutical Market Access Policy Research Center, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2025.06.013
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT